• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA reviews veterinary regenerative medicine and animal cell-based products

October 24, 2016

Currently, no animal cell-based products are FDA-approved, the agency says.

In the fast-growing field of veterinary regenerative medicine, says the U.S. Food and Drug Administration (FDA), cellular material-such as living cells, serum or other products derived from cells-are used in animals with the hope of repairing diseased or damaged tissues or organs. For example, in a horse with tendonitis, the damaged tendon may heal with scar tissue that isn't as strong or elastic as the original tendon, the FDA says. The goal is to transplant living cells into the injured tendon, stimulating it to regenerate and heal. Regenerative medicine is an active area of research for developing new therapies for animals.

Products containing cellular material for use in animals are called animal cell-based products, according to the FDA. Animal stem cells are a subset of cell-based products.

Most animal cell-based products meet the legal definition of “drug” because they are intended to treat, control, or prevent a disease or other condition, such as osteoarthritis, or to affect the structure or function of the body, such as improving fertility, the FDA says. Therefore the agency regulates these products as animal drugs.

Before cell-based drugs can be legally marketed, they must be reviewed and approved by the FDA.

Advertisement

An animal cell-based product that is marketed without FDA approval is an unapproved animal drug. The agency emphasizes that it is illegal to market an unapproved cell-based product because it hasn't gone through the required review process and may not be safe, effective, properly manufactured or properly labeled. Currently, no animal cell-based products are FDA-approved, the agency says.

In June 2015, FDA issued Guidance for Industry (GFI) No. 218, which discusses the approval requirements for animal cell-based products that meet the legal definition of “drug” and how the agency intends to regulate them.

The FDA also sent a letter to all U.S. veterinary schools informing them of the June 2015 guidance. The FDA stated in the letter that veterinary schools that manufacture, market or investigate animal cell-based products should be aware of the regulatory requirements and their responsibilities regarding these products.

In recent years, the scientific community has made significant advances in developing cell-based products for use in animals, the FDA states, but the ultimate proof rests in obtaining high-quality data from well-conducted, well-controlled and well-designed scientific studies.

Because of the complex nature of these products, the FDA is encouraging individuals, universities and drug companies interested in these products to contact the agency at 240-402-7002 or AskCVM@fda.hhs.gov.

Related Content:

MedicalRegulatoryBreaking News
Traditional and holistic treatments for giardia
Traditional and holistic treatments for giardia
3 Must-reads for National Poison Prevention Week
3 Must-reads for National Poison Prevention Week
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens

Advertisement

Latest News

Pet Advocacy Network honors outstanding contributions to the pet care community

Traditional and holistic treatments for giardia

ASU trustees approve the creation of a new veterinary school

6 tips for first-time dog owners

View More Latest News
Advertisement